Compliance

How to Prepare for an SFDA GMP Inspection

An SFDA GMP inspection tests whether the quality system on paper is the one the plant actually runs, measured against the SFDA Guide to Good Manufacturing Practice, version 4.4. Visits start for four reasons the SFDA itself lists: a registration application, a change of process or site, routine inspection of a local manufacturer, or a complaint or recall. Expect the team to read your site master file beforehand, ask for lists and records on day one, then pull individual deviations, CAPAs, changes, complaints and training files and follow each one to its evidence. Findings come back graded critical, major or other, and suspensions do follow. Preparation means being able to produce those records, linked and consistent, on request.

The SFDA does not publish a step-by-step inspection procedure for human-medicine manufacturers, so where this guide describes practice rather than SFDA text, it says so. Computerised systems are covered in our Annex 11 guide.

The short answer

  • Know the yardstick. Guide to GMP v4.4, with its revision table dated 21 May 2026. The SFDA has been a PIC/S participating authority since 1 July 2023.
  • Know why you are being visited, and keep the site master file current: inspectors plan from it.
  • Be ready to trace one record end to end. From the batch to the deviation, the CAPA, the change and the training that followed.
  • Answer findings with cause, correction and proof. Not with an argument about the grade.

How SFDA inspections start

The SFDA's GMP Inspection Deficiency Data Trend 2025 opens with the triggers. Visits in 2025 were initiated by:

  • submission of a product registration application through the SDR system;
  • changes to manufacturing processes or manufacturing site locations;
  • routine GMP inspections of local manufacturers under the Inspection Priority Framework for Local Manufacturers;
  • for-cause inspections, including investigations of complaints and product recalls.

The 2023 report adds a fifth: inspection of a new local manufacturer. In practice that is the usual pre-approval, routine and for-cause split.

Pre-approval. In the Regulatory Framework for Drugs Approval v6.3 (section 3.2.1), the assessing department checks whether the manufacturing line is already approved. If not, a visit is scheduled and the inspection report is sent to the company afterwards; variations that concern inspection follow the same logic (section 4.2.1). If you file an eCTD, the GMP evidence in Module 1.7.1 is where the inspection and the dossier meet; see our SFDA eCTD submission guide.

Scale. The 2025 report counts 133 inspection visits: 22% local and 78% overseas, 126 by the SFDA and 7 GCC joint inspections. Non-sterile products featured in 61 visits, sterile in 57, biological in 15. It records 1,377 deficiencies: 87 critical (about 6.3%) and, in the report's text, 743 major (about 54%; its pie chart shows 772). The executive summary records nine manufacturers suspended in 2025, although the year-on-year chart shows eight. The 2023 report counted 113 visits and 1,713 deficiencies, 114 of them critical, and ten suspensions. The SFDA's own summary says the most frequently cited areas were quality management, premises, equipment and documentation. None of these documents sets a notice period for inspections.

The opening meeting and what to hand over

Practice, not SFDA text. The SFDA does not script the opening meeting. What follows is how we organise it, backed by the SFDA's site master file guidance and by ICMRA's pre-inspection request template. That template was written for collaborative hybrid inspections, not by the SFDA, but it is a fair picture of what inspectors ask for early.

Put the people who answer for each area in the room: heads of Production, Quality Control and, where the post exists, Quality Assurance, plus the Qualified Person. Guide to GMP clause 2.5 requires senior management to appoint these key management personnel and requires the heads of Production and Quality Control to be independent of each other, so the team will want to see that on your organisation chart.

Have each of these, from the ICMRA template, ready as a list:

  • the current site master file with its appendices, and the validation master plan including the process, cleaning and computerised systems validation plans;
  • the SOP index with code, title, version and effective date;
  • a summary of major changes since the last inspection: facility and utilities, equipment, key personnel, suppliers, products;
  • suppliers and contractors with their quality agreements;
  • change controls and deviations for the product in scope, with status, classification, dates and linked CAPAs, ideally exportable to a spreadsheet;
  • the list of batches made or attempted, including rejected, reworked and reprocessed ones, with their investigation numbers;
  • layouts with classifications, pressure differentials and flows, and the major equipment list with qualification and calibration status;
  • environmental monitoring and utilities trends with excursions, and the OOS and OOT investigations.

The practical point is the spreadsheet. If the deviation list takes three days to assemble from paper binders, the inspection starts with a finding about your system.

The site master file

SFDA's guidance (OPS-G-086, version 3.1, with a version-table entry dated 9 November 2022) says the file is prepared by the manufacturer and "should provide clear information on the manufacturer's GMP related activities that can be useful in general supervision and in the efficient planning and undertaking of GMP inspections". Chapter 4 of the Guide to GMP lists the Site Master File among the required GMP documents. The guidance sets these expectations:

  • Length and control. Not more than 25 to 30 pages plus appendices, readable on A4, with an edition number, an effective date and a review date. Appendices can be dated and updated independently.
  • Nine content sections. General information; quality management system; personnel; premises and equipment; documentation; production; quality control; distribution, complaints, product defects and recalls; self-inspections.
  • Eight appendices. The manufacturing authorisation, the dosage forms list, the GMP certificate, contract manufacturers and laboratories, organisation charts, layouts and flow charts, water system drawings, and the major equipment list.
  • Saudi specifics. The national address (WASEL) for local manufacturers; a 24-hour telephone contact for defects and recalls; the qualifications and responsibilities of the Technical Manager for local manufacturers; the list of GMP inspections in the last five years with the authority that performed them; buildings listed with their destination markets where production for Saudi Arabia, GCC and other markets sits in different buildings.
  • Computerised systems. Section 4.2.3 asks for a description of GMP-critical computerised systems, excluding equipment-specific PLCs.

Common failure: the file describes the plant as it was approved, not as it runs. Reconcile it against recent change controls.

Records inspectors sample

SFDA's 2025 data gives a sense of weight. By area, the report counts 450 production deficiencies, 282 premises and equipment, 192 quality management, 178 quality control, 159 validation, 142 materials management and 86 personnel. The report's charts label documents (PSF, SOPs) as the largest quality-management category, 114 of 192, and contamination as the largest production category, 134 of 450. Each record type below is paired with the clause that sets the expectation.

Deviations and root cause

Clause 1.8 (vii) of the Guide to GMP requires significant deviations to be fully recorded and investigated to find the root cause, with corrective and preventive action. Clause 1.4 (xiv) adds that root cause analysis should be proportionate and that where human error is suspected it must be justified after checking that process, procedure and system causes were not overlooked. Expect "show me the last five deviations on this line", then a walk through each.

CAPA

Clause 1.4 (xiv) also asks for CAPAs in response to investigations and for monitoring of their effectiveness. The inspector's question is whether the action matches the cause and whether anyone checked afterwards. See our CAPA process guide.

Change control

Clauses 1.4 (xii) and (xiii) require prospective evaluation and approval of planned changes, considering regulatory notification, and an evaluation afterwards to confirm the quality objectives were met. Annex 15 section 11 goes further: written procedures (11.2), quality risk management of the impact (11.4), approval by responsible persons (11.5), supporting data reviewed before approval (11.6) and an effectiveness evaluation after implementation (11.7). Because the SFDA starts an inspection when a process or site changes, this is the record type most tied to the trigger.

Complaints and recalls

Chapter 8 expects written procedures with every complaint documented and assessed for a potential quality defect (8.5), attention to falsification (8.6), a review of previous defect reports for recurring problems (8.12), timely reporting of defects that may lead to a recall or supply restriction (8.15), root cause analysis and CAPA (8.16 to 8.18) and regular trend analysis (8.19). The 2025 report counts only six deficiencies under complaints and recall, but a for-cause inspection starts here, so the file has to be clean.

Product quality review

Clause 1.10 requires periodic or rolling reviews of all authorised products, normally documented annually, covering twelve items from starting materials and in-process controls to deviations, changes, variations, stability, complaints, post-marketing commitments, qualification status and contracts. Clause 1.11 requires the results to be evaluated for corrective action or revalidation, with the effectiveness of those procedures verified during self-inspection. See our product quality review guide for the item-by-item reading.

Training

Clause 2.10 extends training to everyone whose duties take them into production, storage or the laboratories, including maintenance and cleaning staff. Clause 2.11 asks for training on the quality system and GMP, continuing training whose practical effectiveness is periodically assessed, programmes approved by the head of Production or Quality Control, and training records. The SFDA reports 86 personnel deficiencies in 2025, mainly about training and hygiene. An attendance sheet is weak evidence; an assessment tied to the current SOP version is strong.

Data integrity and documentation

Chapter 4 says records are made at the time of each action so that significant activities are traceable (4.8), that alterations are signed, dated and leave the original legible (4.9), and that secure controls protect record integrity throughout retention, validated where appropriate (4.10). Documents are approved, signed and dated, uniquely identifiable and regularly reviewed, with a system that prevents use of superseded versions (4.3 and 4.5). The computerised side is in our Annex 11 guide.

Self-inspection

Chapter 9 requires a pre-arranged programme covering personnel, premises, equipment, documentation, production, quality control, distribution, complaints and recalls, and self-inspection itself (9.1), carried out independently by designated competent persons (9.2) and recorded with proposals for corrective measures and the actions subsequently taken (9.3).

How findings are graded and answered

SFDA's deficiency reports use three grades: critical, major and other. The PIC/S Guidance on Classification of GMP Deficiencies (PI 040-1, 1 January 2019) defines them; the SFDA GMP guide does not restate the definitions, so the PIC/S text is the working reference.

GradePI 040-1 definition, in short
Critical (4.1)A deficiency that has produced, or leads to a significant risk of producing, a product harmful to the patient; also fraud, misrepresentation or falsification of products or data. Several related deficiencies can together make a critical one.
Major (4.2)Not critical, but has produced or may produce a product that does not comply with its marketing authorisation, or does not ensure effective implementation of required GMP controls, or shows a failure in batch release procedures. Several "other" deficiencies can together make a major one.
Other (4.3)A departure from GMP that is neither critical nor major, including cases with too little information to grade higher.
Comment (4.4)A one-off minor discrepancy brought to the manufacturer's attention without being a formal deficiency.

Appendix 3 of PI 040-1 gives examples. Falsified analytical results, absent manufacturing records and unvalidated sterile-product water or HVAC systems are critical. An inadequate change control system, an inadequate deviation system, no or inadequate internal inspection programme and unvalidated test methods are major: quality-system records of the kind listed above.

Responding. For an inspection tied to a registration, the framework folds inspection questions into the same inquiry wave as the evaluation, with a response expected within 60 working days, and allows four waves in total for evaluation, inspection and pricing before the application is rejected (Framework v6.3, 3.2.1 and 3.3). For other inspections, take the deadline from your own inspection report. What we advise, as practice:

  1. Answer per finding, never per category: correction done, root cause with evidence, corrective and preventive actions with owners and dates, and how you will check effectiveness.
  2. Look for the sibling. If one deviation was closed without a root cause, check every closed deviation from the same period and say what you found.
  3. Do not argue the grade in the response. Argue the facts if they are wrong, and fix the system either way.

Readiness checklist

  1. Site master file current to the last change control, with edition number, effective date and review date, and appendices reconciled (OPS-G-086).
  2. Organisation chart naming heads of Production and Quality Control, independent of each other, and the Qualified Person (2.5, 2.6).
  3. Deviation, change control and complaint lists exportable with status, classification, dates and linked CAPA (1.8 vii, 1.4 xii to xiv, 8.5).
  4. Last five closed deviations traceable from batch record to root cause to CAPA to effectiveness check (1.4 xiv).
  5. Last three changes with risk assessment, approval, supporting data and post-change evaluation (Annex 15, 11.2 to 11.7).
  6. Most recent product quality review per product, with the twelve items of 1.10 and the evaluation of 1.11.
  7. Training matrix and competence records for staff in production, storage and the laboratories (2.10, 2.11).
  8. Records created at the time of each action, with signed and dated corrections (4.8, 4.9).
  9. Self-inspection programme, the last two reports and their closed actions (9.1 to 9.3).
  10. Supplier and contractor list with quality agreements and audit evidence (1.4 vi, Chapter 7).
  11. The computerised systems inventory and audit trail review evidence (see the Annex 11 guide).
  12. A named hosting team: who meets the inspectors, who retrieves records, who keeps the log of everything handed over.

Where software helps

Software does not make a plant compliant, but it can shorten the retrieval work that the checklist depends on. In Corpex-eQMS the deviation, CAPA, change control, complaint and product quality review records are separate modules. A CAPA can carry a mandatory effectiveness check with criteria and a due period, a complaint flagged as CAPA-required spawns a CAPA at final approval, and the audit log is append-only and hash-chained, with e-signatures kept in their own append-only table. For teams that want that as eQMS software for SFDA GMP, the Saudi page maps these modules to the clauses of the Guide to GMP.

Frequently Asked Questions

What triggers an SFDA GMP inspection?

SFDA's GMP Inspection Deficiency Data Trend 2025 lists four triggers: a product registration application submitted through the SDR system, a change in manufacturing process or site location, routine inspections of local manufacturers under the Inspection Priority Framework for Local Manufacturers, and for-cause inspections that follow complaints or product recalls.

Do SFDA inspectors use the same deficiency grades as other PIC/S inspectorates?

SFDA's published deficiency reports grade findings as critical, major and other, which are the three grades defined in PIC/S PI 040-1 (1 January 2019). The SFDA GMP guide does not restate the definitions, so use the PIC/S text as the working reference.

Does the SFDA require a site master file?

The SFDA publishes Guidance for the Preparation of a Site Master File (OPS-G-086, version 3.1) for manufacturers whose sites it inspects, and its GMP guide lists the Site Master File among the required GMP documents in Chapter 4. The guidance says that when submitted, the file helps the Authority plan and carry out inspections.

How long do we have to answer inspection findings?

For an inspection linked to a registration application, SFDA's Regulatory Framework v6.3 says questions arrive as an electronic inquiry through the SDR system as one wave for evaluation and inspection, and a response should be received within 60 working days. For other inspections the SFDA GMP guide sets no general response period, so take the deadline from your own inspection report.

Can an inspection lead to suspension?

SFDA's own data says yes. The executive summary of its 2025 report records nine manufacturers suspended (the report's year-on-year chart shows eight), and its 2023 report records ten. The 2025 report calls suspension a regulatory outcome of inspection findings.

Which SFDA GMP guide version applies now?

Version 4.4 of the Guide to Good Manufacturing Practice for Medicinal Products. Its revision table dates the update to 21 May 2026, and the cover page carries the reference OPS-G-080.

Sources

CORPEX Informatics

Enterprise software solutions for pharmaceutical, food, chemical, and manufacturing industries. Headquartered in Egypt, serving regulated industries across the MENA region since 2006.

Preparing your quality system for an SFDA inspection?

See how Corpex-eQMS keeps deviation, CAPA, change control, complaint and product quality review records linked, with an append-only audit trail and e-signatures.

Explore eQMS software for SFDA GMP